Global Etanercept Drugs 麻豆原创 Research Report 2024

Publication ID:

PB505251852

Publication Date:

May 10, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Etanercept, sold under the brand name Enbrel among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor.
The global Etanercept Drugs market was valued at US$ 8764 million in 2023 and is anticipated to reach US$ 10530 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.
The Enbrel market is primarily driven by the demand for effective treatment options for autoimmune diseases. Enbrel (etanercept) is a medication used to treat conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis. The increasing prevalence of autoimmune disorders and the growing recognition of their impact on patient quality of life contribute to market growth. Moreover, advancements in biologic therapies and the demonstrated efficacy of Enbrel in reducing disease symptoms further propel adoption. However, challenges include managing the high cost of biologic treatments and addressing potential side effects. Navigating patient access issues, optimizing treatment protocols, and ensuring long-term safety are ongoing concerns. The market's success relies on continuous research in autoimmune disease management, collaborations between pharmaceutical manufacturers and healthcare providers, and comprehensive patient education on the benefits and potential risks of Enbrel treatment while addressing the evolving challenges associated with autoimmune disease treatment access and affordability.
This report aims to provide a comprehensive presentation of the global market for Etanercept Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Etanercept Drugs.
Report Scope
The Etanercept Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Etanercept Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Etanercept Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Amgen
Pfizer
3SBIO
Celgen Biopharma
Segment by Type
Brands Drugs
Biosimilar Drugs
Segment by Application
Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Etanercept Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Etanercept Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Etanercept Drugs 麻豆原创 Overview
1.1 Product Overview and Scope of Etanercept Drugs
1.2 Etanercept Drugs Segment by Type
1.2.1 Global Etanercept Drugs 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Brands Drugs
1.2.3 Biosimilar Drugs
1.3 Etanercept Drugs Segment by Application
1.3.1 Global Etanercept Drugs 麻豆原创 Value by Application: (2024-2030)
1.3.2 Rheumatoid Arthritis
1.3.3 Juvenile Idiopathic Arthritis
1.3.4 Psoriatic Arthritis
1.3.5 Ankylosing Spondylitis
1.3.6 Other
1.4 Global Etanercept Drugs 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Etanercept Drugs Revenue 2019-2030
1.4.2 Global Etanercept Drugs Sales 2019-2030
1.4.3 Global Etanercept Drugs 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Etanercept Drugs 麻豆原创 Competition by Manufacturers
2.1 Global Etanercept Drugs Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Etanercept Drugs Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Etanercept Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Etanercept Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Etanercept Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Etanercept Drugs, Product Type & Application
2.7 Etanercept Drugs 麻豆原创 Competitive Situation and Trends
2.7.1 Etanercept Drugs 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Etanercept Drugs Players 麻豆原创 Share by Revenue
2.7.3 Global Etanercept Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Etanercept Drugs Retrospective 麻豆原创 Scenario by Region
3.1 Global Etanercept Drugs 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Etanercept Drugs Global Etanercept Drugs Sales by Region: 2019-2030
3.2.1 Global Etanercept Drugs Sales by Region: 2019-2024
3.2.2 Global Etanercept Drugs Sales by Region: 2025-2030
3.3 Global Etanercept Drugs Global Etanercept Drugs Revenue by Region: 2019-2030
3.3.1 Global Etanercept Drugs Revenue by Region: 2019-2024
3.3.2 Global Etanercept Drugs Revenue by Region: 2025-2030
3.4 North America Etanercept Drugs 麻豆原创 Facts & Figures by Country
3.4.1 North America Etanercept Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Etanercept Drugs Sales by Country (2019-2030)
3.4.3 North America Etanercept Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Etanercept Drugs 麻豆原创 Facts & Figures by Country
3.5.1 Europe Etanercept Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Etanercept Drugs Sales by Country (2019-2030)
3.5.3 Europe Etanercept Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Etanercept Drugs 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Etanercept Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Etanercept Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Etanercept Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Etanercept Drugs 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Etanercept Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Etanercept Drugs Sales by Country (2019-2030)
3.7.3 Latin America Etanercept Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Etanercept Drugs 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Etanercept Drugs 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Etanercept Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Etanercept Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Etanercept Drugs Sales by Type (2019-2030)
4.1.1 Global Etanercept Drugs Sales by Type (2019-2024)
4.1.2 Global Etanercept Drugs Sales by Type (2025-2030)
4.1.3 Global Etanercept Drugs Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Etanercept Drugs Revenue by Type (2019-2030)
4.2.1 Global Etanercept Drugs Revenue by Type (2019-2024)
4.2.2 Global Etanercept Drugs Revenue by Type (2025-2030)
4.2.3 Global Etanercept Drugs Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Etanercept Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Etanercept Drugs Sales by Application (2019-2030)
5.1.1 Global Etanercept Drugs Sales by Application (2019-2024)
5.1.2 Global Etanercept Drugs Sales by Application (2025-2030)
5.1.3 Global Etanercept Drugs Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Etanercept Drugs Revenue by Application (2019-2030)
5.2.1 Global Etanercept Drugs Revenue by Application (2019-2024)
5.2.2 Global Etanercept Drugs Revenue by Application (2025-2030)
5.2.3 Global Etanercept Drugs Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Etanercept Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Etanercept Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Etanercept Drugs Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Etanercept Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Etanercept Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 3SBIO
6.3.1 3SBIO Corporation Information
6.3.2 3SBIO Description and Business Overview
6.3.3 3SBIO Etanercept Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 3SBIO Etanercept Drugs Product Portfolio
6.3.5 3SBIO Recent Developments/Updates
6.4 Celgen Biopharma
6.4.1 Celgen Biopharma Corporation Information
6.4.2 Celgen Biopharma Description and Business Overview
6.4.3 Celgen Biopharma Etanercept Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Celgen Biopharma Etanercept Drugs Product Portfolio
6.4.5 Celgen Biopharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Etanercept Drugs Industry Chain Analysis
7.2 Etanercept Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Etanercept Drugs Production Mode & Process
7.4 Etanercept Drugs Sales and 麻豆原创ing
7.4.1 Etanercept Drugs Sales Channels
7.4.2 Etanercept Drugs Distributors
7.5 Etanercept Drugs Customers
8 Etanercept Drugs 麻豆原创 Dynamics
8.1 Etanercept Drugs Industry Trends
8.2 Etanercept Drugs 麻豆原创 Drivers
8.3 Etanercept Drugs 麻豆原创 Challenges
8.4 Etanercept Drugs 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Amgen
Pfizer
3SBIO
Celgen Biopharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.